The Journal of Clinical Endocrinology & Metabolism · 2014 · 55 citations · 25 references
MedicineEndocrinologyOncologyEndocrine OncologyNeoplasiaTumor ImmunologyNeuroendocrine TumorsThyroid CancerThyroid CytologyThyroid UltrasonographyThyroid UltrasoundTumor MarkersCarcinoembryonic Antigen ImagingMedullary Thyroid Carcinoma CytologyMedullary Thyroid Carcinoma DiagnosisMedullary Thyroid Carcinoma PathologyNeedle Aspiration BiopsyThyroid Cancer PathologyThyroid Nodule CytologyThyroid Nodule Cytopathology
CONTEXT: Calcitonin is a sensitive biomarker that is used for diagnosis and follow-up in medullary thyroid cancer (MTC). In patients with tumors > 1 cm, it is uncommon for preoperative serum calcitonin to be in the normal laboratory reference range in patients with MTC, and even more unusual for serum calcitonin to be undetectable. THE CASE: A 39-year-old woman was found to have a left thyroid nodule on magnetic resonance imaging done for neck pain. Ultrasound and fine-needle aspiration biopsy were performed, and cytopathology was positive for malignant cells. The cells also had features suggestive of a neuroendocrine tumor, and the specimen was immune-stained with calcitonin. There was positive immunoreactivity for calcitonin in isolated cells of the cytospin, highly favoring a diagnosis of MTC. Serum calcitonin was < 2 pg/mL (<6 pg/mL), and serum carcinoembryonic antigen was 3.1 ng/mL (<5.2 ng/mL). Given the low calcitonin levels, procalcitonin was also tested and was elevated at 0.21 ng/mL (< 0.1 ng/mL). The patient subsequently underwent a total thyroidectomy and central and ipsilateral lateral lymph node dissection. Histopathology confirmed a 2.6 × 2.0 × 1.2-cm MTC, with strong, diffuse immunostaining for calcitonin. Postoperatively, serum calcitonin has remained undetectable, carcinoembryonic antigen has remained within the reference range, and procalcitonin has become undetectable. CONCLUSIONS: We present a rare case of a patient with MTC with undetectable preoperative serum calcitonin, whose tumor demonstrated strong, diffuse immunohistochemical staining for calcitonin. We discuss the possible pathogenesis of calcitonin-negative MTC and the challenges in following patients with this condition.
25
Scott A. Hundahl, Irvin D. Fleming, Amy M. Fremgen et al. · Cancer · 1998 · 1.8K citations · Full text
Medicine, Oncology, Cancer Control +16
Prognostic factors for thyroid carcinoma
Frank D. Gilliland, William C. Hunt, Don M. Morris et al. · Cancer · 1997 · 805 citations · Full text
Electron Kebebew, Philip H. G. Ituarte, Allan Siperstein et al. · Cancer · 2000 · 683 citations · Full text
Medicine, Endocrinology, Oncology +11
Giuseppe Costante, Domenico Meringolo, Cosimo Durante et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 374 citations
Medicine, Endocrinology, Radiology +17